首页|期刊导航|浙江大学学报(医学版)|注射型和透皮型糖响应胰岛素递释系统研究进展

注射型和透皮型糖响应胰岛素递释系统研究进展OA

Advances in injectable and transdermal glucose-responsive insulin delivery systems

中文摘要英文摘要

为克服传统胰岛素治疗中血糖调控滞后和低血糖频发的核心难题,开发能够动态响应血糖变化、实现胰岛素按需释放的糖响应胰岛素递释系统是重要策略.根据糖响应胰岛素递释系统作用机制不同,可分为基于葡萄糖氧化酶的系统、基于葡萄糖结合分子的系统和基于苯硼酸的系统.从给药途径出发,注射给药和透皮给药是糖响应胰岛素递释系统的两种主要给药途径.注射型糖响应胰岛素递释系统给药方式与现有临床治疗模式高度兼容,主要依赖糖响应载体调控胰岛素释放速率,能够实现稳定且较高的生物利用度.透皮型糖响应胰岛素递释系统则借助糖响应微针阵列穿透皮肤角质层并精准调控胰岛素释放速率,可在近乎无痛的条件下实现足量胰岛素递送.本文系统梳理注射型和透皮型糖响应胰岛素递释系统的研究进展,重点阐述这两类递释系统的载体构建策略、糖响应释放机制及制备工艺演化路径,介绍其在提高胰岛素糖响应释放性能、治疗安全性、生物相容性及患者依从性等方面的推动作用,并展望其在临床转化中面临的挑战及未来发展方向,以期能为糖响应胰岛素递释系统的未来研究提供借鉴.

To address the core limitations of conventional insulin therapy,including delayed glycemic control and the frequent risk of hypoglycemia,the development of glucose-responsive insulin delivery systems capable of dynamically sensing blood glucose levels and releasing insulin on demand has emerged as a pivotal strategy.Based on their underlying sensing mechanisms,these systems are generally classified into three categories:those utilizing glucose oxidase,glucose-binding molecules,and phenylboronic acid.From the perspective of administration routes,injectable and transdermal delivery are the two primary approaches for glucose-responsive insulin.Injectable glucose-responsive insulin delivery systems are highly compatible with existing clinical practices,primarily relying on glucose-responsive carriers to regulate the insulin release rate and achieve stable and efficient bioavailability.Transdermal glucose-responsive insulin delivery systems utilize glucose-responsive microneedle arrays to penetrate the skin stratum corneum and precisely control the rate of insulin release,allowing for sufficient insulin delivery under almost painless conditions.This review systematically summarizes recent advances in both injectable and transdermal glucose-responsive insulin delivery systems,with a focus on carrier design strategies,glucose-responsive release mechanisms,and evolutionary pathways of preparation techniques.It also highlights the contributions of these systems toward improved glucose-responsiveness,therapeutic safety,biocompatibility,and patient adherence.Furthermore,challenges and future prospects for clinical translation are discussed.This overview is expected to provide valuable insights for further research and development in this field.

李凯惠;张秀雯;顾臻;王金强

浙江大学药学院 先进药物递释系统全国重点实验室,浙江 杭州 310058浙江大学药学院 先进药物递释系统全国重点实验室,浙江 杭州 310058浙江大学药学院 先进药物递释系统全国重点实验室,浙江 杭州 310058||浙江大学金华研究院,浙江 金华 321299||浙江大学良渚实验室,浙江 杭州 311121||浙江大学高分子科学与工程学系 高分子合成与功能构造教育部重点实验室,浙江 杭州 310027||浙江大学基础交叉研究院,浙江 杭州 310058||浙江大学医学院附属邵逸夫医院普外科,浙江 杭州 310016||浙江大学医学院附属第二医院药学部,浙江 杭州 310009浙江大学药学院 先进药物递释系统全国重点实验室,浙江 杭州 310058||浙江大学金华研究院,浙江 金华 321299||浙江大学医学院附属第二医院药学部,浙江 杭州 310009

医药卫生

糖尿病葡萄糖响应胰岛素递释系统注射制剂透皮制剂长效制剂微针综述

Diabetes mellitusGlucose-responsive insulin delivery systemInjectable preparationTransdermal preparationLong-acting preparationMicroneedleReview

《浙江大学学报(医学版)》 2026 (1)

16-26,11

国家自然科学基金(32471374)This study was supported by National Natural Science Foundation of China (32471374)

10.3724/zdxbyxb-2025-0656

评论